Search:
Tokushima UniversityGraduate School of Biomedical Sciences医学域Endwed Collaborative ResearchContributionDepartment of Community Medicine and Medical Science
Tokushima UniversityResearch ClustersResearch Clusters (Registered)1904011 がん化学療法中の全身性免疫炎症病態へのFusobacteriumの役割の解明と有効な支持療法および簡便なFusobacterium検出法の開発
(Files for researchmap) [PDF manual] [Auto-propagate to researchmap]

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Book:

1. Kumiko Kagawa, 前田 悠作, Masahiro Oura, Kimiko Sogabe, 藤野 ひかる, 髙橋 真美子, 丸橋 朋子, 岩佐 昌美, 宇高 憲吾, Takeshi Harada, Takayuki Ise, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Shusuke Yagi, Kyoko Takeuchi, Shuji Ozaki, Masahiro Abe and 藤野 ひかる :
Analysis of long-term survivors with cardiac AL amyloidosis,
The Japanese Society of Hematology, Oct. 2017.
(DOI: 10.11406/rinketsu.58.2197,   CiNii: 1390282680011466240)
2. Masahiro Abe, Hirokazu Miki and Shingen Nakamura :
Management of bone disease in myeloma patients: zoledronic acid or denosumab?,
The Japanese Society of Hematology, 2015.
(DOI: 10.11406/rinketsu.56.997,   CiNii: 1390001205035009152)
3. Shingen Nakamura and Masahiro Abe :
臓器移植.ALアミロイドーシス,多発性骨髄腫の類縁疾患,
Iyaku Journal Co., Ltd., Aug. 2014.
4. Shingen Nakamura and Masahiro Abe :
アミロイドーシス効果判定基準 効果判定基準 2005コンセンサスクライテリア,2011新基準.ALアミロイドーシス,多発性骨髄腫の類縁疾患,
Iyaku Journal Co., Ltd., Aug. 2014.
5. Shingen Nakamura :
(chapter6),
Jan. 2014.
6. Shingen Nakamura, Masahiro Abe and Toshio Matsumoto :
新規治療薬の開発と臨床応用の可能性を探る (抗RANKL抗体などを中心に),
Mar. 2012.

Academic Paper (Judged Full Paper):

1. Naoto Okada, Akikazu Murakami, Masami Satou, Shingen Nakamura, Shiroh Fujii, Kimiko Sogabe, Mamiko Takahashi, Asami Okada, Akane Abe, Hideki Fujii, Masahiro Abe, Momoyo Azuma and Keisuke Ishizawa :
First reported case of Lachnoanaerobaculum gingivalis bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy.,
Anaerobe, Vol.76, 2022.
(DOI: 10.1016/j.anaerobe.2022.102610,   PubMed: 35811059)
2. Hiroki Yamada, Rio Ohmori, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
A machine learning model using SNPs obtained from a genome-wide association study predicts the onset of vincristine-induced peripheral neuropathy,
The Pharmacogenomics Journal, 2022.
(Tokushima University Institutional Repository: 117583,   DOI: 10.1038/s41397-022-00282-8,   PubMed: 35752658)
3. Minori Takei, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
A genome-wide association study predicts the onset of dysgeusia due to anti-cancer drug treatment,
Biological & Pharmaceutical Bulletin, Vol.45, No.1, 114-117, 2022.
(Tokushima University Institutional Repository: 117584,   DOI: 10.1248/bpb.b21-00745,   PubMed: 34657909)
4. 西條 早希, Shingen Nakamura, Hirokazu Miki, 谷口 早紀, 岡本 秀樹, 富永 誠記, Naoto Okada, 矢野 由美子, 髙橋 真理, Keiko Aota, Toshiyuki Suge, Hiroyoshi Watanabe, 大坂 朱美 and Masahiro Abe :
徳島大学病院における先天性血友病患者(成人例)の実態調査∼移行期医療の重要性∼,
Shikoku Acta Medica, Vol.77, No.5-6, 261-268, 2021.
(CiNii: 1050855267567099520)
5. Naoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu, Masaki Morishima, Yasuyuki Nagata, Hiroshi Kosugi, Yoshimitsu Shimomura, Ichiro Hanamura, Shigeo Fuji, Koichiro Minauchi, Junya Kuroda, Rikio Suzuki, Noriko Nishimura, Nobuhiko Uoshima, Hirohisa Nakamae, Yawara Kawano, Ishikazu Mizuno, Hiroshi Gomyo, Kenshi Suzuki, Shuji Ozaki, Shingen Nakamura, Yoichi Imai, Masahiro Kizaki, Eiju Negoro, Hiroshi Handa and Shinsuke Iida :
Expression of activated integrin β7 in multiple myeloma patients.,
International Journal of Hematology, Vol.114, No.1, 3-7, 2021.
(DOI: 10.1007/s12185-021-03162-2,   PubMed: 33999338)
6. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Asuka Oda, Ariunzaya Bat-Erdene, Takeshi Harada, Shingen Nakamura, Mohannad Ashtar, Sou Shimizu, Masami Iwasa, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma,
Haematologica, Vol.106, No.5, 1401-1413, 2021.
(Tokushima University Institutional Repository: 116529,   DOI: 10.3324/haematol.2019.234476,   PubMed: 32273474)
7. Ryohei Sumitani, Taiki Hori, Jumpei Murai, Shiyori Kawata, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura :
Acute Myeloid Leukemia Developing with Acute Pancreatitis Mimicking Autoimmune Pancreatitis.,
Internal Medicine, Vol.60, No.11, 1753-1757, 2021.
(Tokushima University Institutional Repository: 116536,   DOI: 10.2169/internalmedicine.4916-20,   PubMed: 33456032)
8. Tashima Hozumi, Endo Yuka, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
Association analysis between adverse drug reactions to cytarabine therapy and single nucleotide polymorphisms in cytarabine metabolic genes in patients with hematopoietic tumor,
Personalized Medicine Universe, Vol.10, 1-6, 2021.
(DOI: 10.46459/pmu.2021002)
9. Mamiko Takahashi, Ryohei Sumitani, Taiki Hori, Jumpei Murai, Shiyori Kawata, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura :
Intravenous busulfan-based conditioning with autologous stem cell transplantation for refractory B-cell lymphoma with central nervous system involvement.,
The Journal of Medical Investigation : JMI, Vol.68, No.1.2, 196-201, 2021.
(Tokushima University Institutional Repository: 116021,   DOI: 10.2152/jmi.68.196,   PubMed: 33994471)
10. Yuka Sogawa, Makoto Fukui, Shingen Nakamura, Kimiko Sogabe, Ryohei Sumitani, Masami Yoshioka, Masahiro Abe and Daisuke Hinode :
Involvement of oral bacteria and oral immunity as risk factors for chemotherapy- induced fever with neutropenia in patients with hematological cancer,
International Journal of Hematology, Vol.112, No.6, 851-859, 2020.
(Tokushima University Institutional Repository: 115932,   DOI: 10.1007/s12185-020-02975-x,   PubMed: 32880823,   Elsevier: Scopus)
11. Shun-Ichi Kimura, Yoshinobu Kanda, Masaki Iino, Takahiro Fukuda, Emiko Sakaida, Tatsuo Oyake, Hiroki Yamaguchi, Shin-Ichiro Fujiwara, Yumi Jo, Akinao Okamoto, Hiroyuki Fujita, Yasushi Takamatsu, Yoshio Saburi, Itaru Matsumura, Jun Yamanouchi, Souichi Shiratori, Moritaka Gotoh, Shingen Nakamura and Kazuo Tamura :
Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial.,
International Journal of Infectious Diseases : IJID, Vol.100, 292-297, 2020.
(Tokushima University Institutional Repository: 116538,   DOI: 10.1016/j.ijid.2020.08.081,   PubMed: 32891738)
12. Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masahiro Hiasa, Asuka Oda, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Shiroh Fujii, Ryohei Sumitani, Hirokazu Miki, Kengo Udaka, Mamiko Takahashi, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat.,
Cancers, Vol.12, No.4, 2020.
(Tokushima University Institutional Repository: 115041,   DOI: 10.3390/cancers12040929,   PubMed: 32283857)
13. Kengo Udaka, Shingen Nakamura, Shiroh Fujii, Ryosuke Miyamoto, Naoko Matsui, Shiyori Kawata, Taiki Hori, Junpei Murai, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Mamiko Takahashi, Takeshi Harada, Kumiko Kagawa, Yuishin Izumi, Masahiro Abe and Hirokazu Miki :
Successful treatment of progressive multifocal leukoencephalopathy with mirtazapine and mefloquine in refractory myeloma,
International Journal of Myeloma, Vol.10, No.1, 8-12, 2020.
14. Shuji Ozaki, Takeshi Harada, Hikaru Yagi, Etsuko Sekimoto, Hironobu Shibata, Toshio Shigekiyo, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma,
Cancers, Vol.12, No.1, 12, 2019.
(Tokushima University Institutional Repository: 115047,   DOI: 10.3390/cancers12010012,   PubMed: 31861479,   Elsevier: Scopus)
15. Naoto Okada, Masayuki Chuma, Momoyo Azuma, Shingen Nakamura, Hirokazu Miki, Hirofumi Hamano, Mitsuhiro Goda, Kenshi Takechi, Yoshito Zamami, Masahiro Abe and Keisuke Ishizawa :
Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study.,
European Journal of Clinical Pharmacology, Vol.75, No.12, 1695-1704, 2019.
(DOI: 10.1007/s00228-019-02756-4,   PubMed: 31511938)
16. 井上 雄介, Akishige Ikegame, 徳永 尚樹, 千尋 井上, Takayuki Nakao, Kojiro Nagai, 高橋 真美子, Shiroh Fujii, Shingen Nakamura and Masahiro Abe :
芽球様の形態を示した肝脾型T細胞リンパ腫の一症例,
日本検査血液学会雑誌, Vol.20, No.2, 231-237, 2019.
17. Masami Iwasa, Takeshi Harada, Asuka Oda, Ariunzaya Bat-Erdene, Jumpei Teramachi, Hirofumi Tenshin, Mohannad Ashtar, Masahiro Oura, Kimiko Sogabe, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki and Masahiro Abe :
PD-L1 upregulation in myeloma cells by panobinostat in combination with interferon-γ.,
Oncotarget, Vol.10, No.20, 1903-1917, 2019.
(Tokushima University Institutional Repository: 113359,   DOI: 10.18632/oncotarget.26726,   PubMed: 30956773,   Elsevier: Scopus)
18. Yuko Miyakami, Shingen Nakamura, Masahiro Oura, Yasunobu Okamoto, 高橋 真美子, Kimiko Sogabe, 岩佐 昌美, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hisanori Uehara and Masahiro Abe :
De novo CD 20-negative diffuse large B-cell lymphoma developed with sustained fever and markedly high C-reactive protein level,
Shikoku Acta Medica, Vol.74, No.5-6, 193-200, 2018.
(Tokushima University Institutional Repository: 112987,   CiNii: 1050845763422780928)
19. Ariunzaya Bat-Erdene, Shingen Nakamura, Asuka Oda, Masami Iwasa, Jumpei Teramachi, Mohannad Ashtar, Takeshi Harada, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa, Shiroh Fujii, Kimiko Sogabe, Masahiro Oura, Kengo Udaka, Kumiko Kagawa, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Itsuro Endo and Masahiro Abe :
Class 1 HDAC and HDAC6 inhibition inversely regulates CD38 induction in myeloma cells via interferon-α and ATRA.,
British Journal of Haematology, 2018.
(Tokushima University Institutional Repository: 113393,   DOI: 10.1111/bjh.15673,   PubMed: 30474853,   Elsevier: Scopus)
20. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Takeshi Harada, Shingen Nakamura, Ryota Amachi, Hirofumi Tenshin, Masami Iwasa, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pim-2 is a critical target for treatment of osteoclastogenesis enhanced in myeloma.,
British Journal of Haematology, Vol.180, No.4, 581-585, 2018.
(Tokushima University Institutional Repository: 112935,   DOI: 10.1111/bjh.14388,   PubMed: 27748523)
21. Shingen Nakamura, Momoyo Azuma, Tomoko Maruhashi, Kimiko Sogabe, Ryohei Sumitani, Munenori Uemura, Masami Iwasa, Shiro Fujii, Hirokazu Miki, Kumiko Kagawa, Takashi Hiraga, Noriyasu Kondo, Hiromi Fujita, Fumihiko Mahara and Masahiro Abe :
Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome.,
Journal of Infection and Chemotherapy, Vol.24, No.5, 389-392, 2018.
(Tokushima University Institutional Repository: 113012,   DOI: 10.1016/j.jiac.2017.11.004,   PubMed: 29428565)
22. Shiroh Fujii, Shingen Nakamura, Asuka Oda, Hirokazu Miki, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Itsuro Endo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Takeshi Harada, Kumiko Kagawa, Michiyasu Nakao, Shigeki Sano and Masahiro Abe :
Unique anti-myeloma activity by thiazolidine-2,4-dione compounds with Pim inhibiting activity.,
British Journal of Haematology, Vol.180, No.2, 246-258, 2018.
(Tokushima University Institutional Repository: 112752,   DOI: 10.1111/bjh.15033,   PubMed: 29327347,   Elsevier: Scopus)
23. 山口 純代, Shingen Nakamura, 住田 智志, 前田 悠作, Masahiro Oura, 高橋 真美子, 岩佐 昌美, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Jun Kishi and Masahiro Abe :
Development of adult T-cell leukemia/lymphoma during immunosuppressive Therapy for human T-cell leukemia virus type 1 associated arthropathy,
Shikoku Acta Medica, Vol.73, No.5,6, 301-308, 2017.
(Tokushima University Institutional Repository: 112059,   CiNii: 1050001338847982080)
24. Hirokazu Miki, Shingen Nakamura, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Yusaku Maeda, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kiyoe Kurahashi, Sumiko Yoshida, Kumiko Kagawa, Itsuro Endo, Aihara Kenichi, Mariko Ikuo, Kouji Itou, Koichiro Hayashi, Michihiro Nakamura and Masahiro Abe :
Effective impairment of myeloma cells and their progenitors by hyperthermia.,
Oncotarget, Vol.9, No.12, 10307-10316, 2017.
(Tokushima University Institutional Repository: 113059,   DOI: 10.18632/oncotarget.23121,   PubMed: 29535808,   Elsevier: Scopus)
25. Hirofumi Tenshin, Jumpei Teramachi, Asuka Oda, Ryota Amachi, Masahiro Hiasa, Ariunzaya Bat-Erdene, Keiichiro Watanabe, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Kiyoe Kurahashi, Sumiko Yoshida, Kenichi Aihara, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects.,
Blood Advances, Vol.1, No.24, 2124-2137, 2017.
(Tokushima University Institutional Repository: 111724,   DOI: 10.1182/bloodadvances.2017008813,   PubMed: 29296860)
26. Shingen Nakamura :
Multiple myeloma with high adenosine deaminase expression,
International Journal of Myeloma, Vol.7, No.1, 1-5, 2017.
(Tokushima University Institutional Repository: 114702,   CiNii: 1050285299745547520)
27. Ariunzaya Bat-Erdene, Hirokazu Miki, Asuko Oda, Shingen Nakamura, Jumpei Teramachi, Ryota Amachi, Hirofumi Tenshin, Masahiro Hiasa, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kimiko Sogabe, Kumiko Kagawa, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara and Masahiro Abe :
Synergistic targeting of Sp1, a critical transcription factor for myeloma cell growth and survival, by panobinostat and proteasome inhibitors.,
Oncotarget, Vol.7, No.48, 79064-79075, 2016.
(Tokushima University Institutional Repository: 109988,   DOI: 10.18632/oncotarget.12594,   PubMed: 27738323)
28. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Takeshi Harada, Asuka Oda, Shingen Nakamura, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masami Iwasa, Itsuro Endo, Takeshi Kondo, Sumiko Yoshida, Ken-ichi Aihara, Kiyoe Kurahashi, Yoshiaki Kuroda, Hideaki Horikawa, Eiji Tanaka, Masahiro Abe and Toshio Matsumoto :
A vicious cycle between acid sensing and survival signaling in myeloma cells: acid-induced epigenetic alteration.,
Oncotarget, Vol.7, No.43, 70447-70461, 2016.
(Tokushima University Institutional Repository: 113048,   DOI: 10.18632/oncotarget.11927,   PubMed: 27626482)
29. Takeshi Harada, Hirokazu Miki, Q Cui, A Oda, Ryota Amachi, Jumpei Teramachi, A Bat-Erdene, K Sogabe, M Iwasa, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Sumiko Yoshida, I Endo, Ken-ichi Aihara, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Expansion of Th1-like V9V2T cells by new-generation IMiDs, lenalidomide and pomalidomide, in combination with zoledronic acid.,
Leukemia, Vol.31, No.1, 258-262, 2016.
(DOI: 10.1038/leu.2016.273,   PubMed: 27698446)
30. Naoto Okada, Shuji Fushitani, Momoyo Azuma, Shingen Nakamura, Toshimi Nakamura, Kazuhiko Teraoka, Hiroyoshi Watanabe, Masahiro Abe, Kazuyoshi Kawazoe and Keisuke Ishizawa :
Clinical evaluation of pharmacist interventions in patients treated with anti-methicillin-resistant Staphylococcus aureus agents in a hematological ward,
Biological & Pharmaceutical Bulletin, Vol.39, No.2, 295-300, 2015.
(DOI: 10.1248/bpb.b15-00774,   PubMed: 26830489)
31. James Derek Hanson, Shingen Nakamura, Ryota Amachi, Masahiro Hiasa, Asuka Oda, Daisuke Tsuji, Kohji Itoh, Takeshi Harada, Kazuki Horikawa, Jumpei Teramachi, Hirokazu Miki, Toshio Matsumoto and Masahiro Abe :
Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation.,
Oncotarget, Vol.6, No.32, 33568-33586, 2015.
(Tokushima University Institutional Repository: 109501,   DOI: 10.18632/oncotarget.5598,   PubMed: 26384349,   Elsevier: Scopus)
32. Michiko Yamashita, Yoshiyuki Fujii, Keiji Ozaki, Yoshio Urano, Masami Iwasa, Shingen Nakamura, Shiroh Fujii, Masahiro Abe, Yasuharu Sato and Tadashi Yoshino :
Human immunodeficiency virus-positive secondary syphilis mimicking cutaneous T-cell lymphoma.,
Diagnostic Pathology, Vol.10, 185, 2015.
(DOI: 10.1186/s13000-015-0419-5,   PubMed: 26449225,   Elsevier: Scopus)
33. Shingen Nakamura, Hirokazu Miki, Asuka Oda, Ryota Amachi, Jumpei Teramachi, Kimiko Sogabe, Hikaru Fujino, Tomoko Maruhashi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Susceptibility to bendamustine considerably varies among myeloma cells, but is enhanced in acidic conditions,
International Journal of Myeloma, Vol.6, No.1, 7-11, 2015.
34. T Watanabe, M Mitsuhashi, M Sagawa, M Ri, K Suzuki, Masahiro Abe, K Ohmachi, Y Nakagawa, Shingen Nakamura, S Iida and M Kizaki :
Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma,
PLoS ONE, Vol.10, No.6, e0128662, 2015.
(Tokushima University Institutional Repository: 114924,   DOI: 10.1371/journal.pone.0128662,   PubMed: 26115406,   Elsevier: Scopus)
35. Hirokazu Miki, Shingen Nakamura, A Oda, R Amachi, Keiichiro Watanabe, D Hanson, Jumpei Teramachi, Masahiro Hiasa, H Yagi, K Sogabe, M Takahashi, T Maruhashi, K Udaka, T Harada, Shiroh Fujii, A Nakano, Kumiko Kagawa, M Ri, S Iida, Shuji Ozaki, T Matsumoto and Masahiro Abe :
Induction of endoplasmic reticulum stress by bortezomib sensitizes myeloma cells to DR5-mediated cell death,
International Journal of Myeloma, Vol.5, No.1, 1-7, 2015.
(DOI: 10.57352/ijm.5.1_1,   CiNii: 1390292815284471040)
36. Kumiko Kagawa, Shingen Nakamura, 八木 ひかる, Kimiko Sogabe, 髙橋 真美子, 丸橋 朋子, 宇髙 憲吾, Shiroh Fujii, Hirokazu Miki and Masahiro Abe :
Successful treatment of refractory severe aplastic anemia with bone marrow transplantation from a genetically identical twin,
Shikoku Acta Medica, Vol.70, No.3,4, 77-80, 2014.
(Tokushima University Institutional Repository: 109757,   CiNii: 1050001337464993408)
37. Masahiro Hiasa, Jumpei Teramachi, A Oda, Ryota Amachi, T Harada, Shingen Nakamura, Hirokazu Miki, Shiroh Fujii, Kumiko Kagawa, Keiichiro Watanabe, Itsuro Endo, Y Kuroda, T Yoneda, Daisuke Tsuji, Michiyasu Nakao, Eiji Tanaka, Kenichi Hamada, Shigeki Sano, Kouji Itou, Toshio Matsumoto and Masahiro Abe :
Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma.,
Leukemia, 2014.
(DOI: 10.1038/leu.2014.147,   PubMed: 24787487)
38. Takeshi Harada, Shuji Ozaki, Asuka Oda, Daisuke Tsuji, Akishige Ikegame, Masami Iwasa, Kengo Udaka, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Yoshiaki Kuroda, Shigeto Kawai, Kouji Itou, Hisafumi Yamada-Okabe, Toshio Matsumoto and Masahiro Abe :
Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors,
PLoS ONE, Vol.8, No.12, e83905, 2013.
(Tokushima University Institutional Repository: 106068,   DOI: 10.1371/journal.pone.0083905,   PubMed: 24386306,   Elsevier: Scopus)
39. Shingen Nakamura, Hirokazu Miki, Shinsuke Kido, Ayako Nakano, Masahiro Hiasa, Asuka Oda, Hiroe Amou, Keiichiro Watanabe, Takeshi Harada, Shiroh Fujii, Kyoko Takeuchi, Kumiko Kagawa, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Activating transcription factor 4, an ER stress mediator, is required for, but exce ssive ER stress suppresses osteoblastogenesis by bortezomib.,
International Journal of Hematology, Vol.98, No.1, 66-73, 2013.
(Tokushima University Institutional Repository: 105938,   DOI: 10.1007/s12185-013-1367-z,   PubMed: 23708974,   Elsevier: Scopus)
40. Keisuke Fujioka, Atsuro Saijo, Yuko Toyoda, Souji Kakiuchi, Masaki Hanibuchi, Masahiko Azuma, Kyoko Takeuchi, Shiroh Fujii, Shingen Nakamura, Kengo Utaka, Kumiko Kagawa, Masahiro Abe, Tomoya Mizutani and Yasuhiko Nishioka :
皮膚ランダム生検が診断に有用であった血管内リンパ腫の一例,
Shikoku Acta Medica, Vol.67, No.5,6, 257-262, 2011.
(Tokushima University Institutional Repository: 97858,   CiNii: 1050001337463886208)
41. Hirokazu Miki, Shingen Nakamura, Shuji Ozaki, A Oda, H Amou, Akishige Ikegame, Keiichiro Watanabe, Masahiro Hiasa, Q Cui, T Harada, Shiroh Fujii, A Nakano, Kumiko Kagawa, Kyoko Takeuchi, Ken-ichiro Yata, A Sakai, Masahiro Abe and Toshio Matsumoto :
KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts.,
British Journal of Haematology, Vol.155, No.3, 328-339, 2011.
(DOI: 10.1111/j.1365-2141.2011.08844.x,   PubMed: 21902681)
42. Qu Cui, Hironobu Shibata, Asuka Oda, Hiroe Amou, Ayako Nakano, Kenichiro Yata, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Targeting myeloma-osteoclast interaction with V9V2 T cells.,
International Journal of Hematology, Vol.94, No.1, 63-70, 2011.
(DOI: 10.1007/s12185-011-0885-9,   PubMed: 21698356)
43. Shingen Nakamura, Kenichiro YATA, Tadashi JINNO, Takeshi HARADA, Shiro FUJII, Hirokazu MIKI, Ayako NAKANO, Kumiko KAGAWA, Kyoko TAKEUCHI, Shuji OZAKI, Masahiro Abe and Toshio MATSUMOTO :
Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy,
The Japanese Journal of Clinical Hematology, Vol.51, No.8, 690-695, 2010.
(DOI: 10.11406/rinketsu.51.690,   PubMed: 20805677,   CiNii: 1390001205037088512,   Elsevier: Scopus)
44. Shingen Nakamura, Shigeaki Kimura, Masahiro Kashima, Kana Shichijo, Sumiko Yoshida, Eiji Harada, Takaya Matsushita, Yasutami Tamaki, Noriaki Horiuchi, Toshiaki Takeichi, Hiroshi Fujimoto, Kazuhiko Masuda, Naohito Iwasaka and Sadao Shinomiya :
[A case of peritonitis carcinomatosa from goblet cell carcinoid of the appendix treated by intraperitoneal paclitaxel and systemic S-1 chemotherapy].,
Japanese Journal of Cancer and Chemotherapy, Vol.35, No.13, 2425-2428, 2008.
(PubMed: 19098416)
45. Shingen Nakamura, Noriaki Horiuchi, Daisuke Katsura, Kana Shichijo, Sumiko Yoshida, Eiji Harada, Takaya Matsushita, Yasuyuki Matsuzaki, Yasutami Tamaki, Shigeaki Kimura, Toshiaki Takeichi, Hiroshi Fujimoto, Kazuhiko Masuda, Naohito Iwasaka and Sadao Shinomiya :
[A long-surviving patient with lung pleomorphic carcinoma treated with postoperative carboplatin and paclitaxel combination chemotherapy].,
Japanese Journal of Cancer and Chemotherapy, Vol.35, No.6, 965-968, 2008.
(PubMed: 18633226,   Elsevier: Scopus)

Academic Paper (Unrefereed Paper):

1. Shingen Nakamura, Masahiro Abe and Toshio Matsumoto :
Part7. 2. 新規治療薬の開発と臨床応用の可能性を探る (抗RANKL抗体などを中心に). がん骨転移治療 ビスフォスフォネート治療によるBone Management,
先端医学者 高橋俊二 編集, 206-214, 2012.

Review, Commentary:

1. Shingen Nakamura and Masahiro Abe :
【骨粗鬆症 最新の知見に基づいた治療薬の考え方・使い方】薬剤性骨粗鬆症に対するマネジメントの勘所 がん治療に伴う骨粗鬆症,
The Journal of Practical Pharmacy, Vol.71, No.11, 3313-3321, Oct. 2020.
2. Shingen Nakamura and Masahiro Abe :
骨髄腫骨病変の治療,
Hematology, Vol.69, No.4, 525-533, Oct. 2014.
3. Shingen Nakamura and Masahiro Abe :
【続発性骨粗鬆症-診断と対策-】移植医療と骨粗鬆症,
THE BONE, Vol.27, No.2, 187-192, May 2013.
4. Shingen Nakamura and Masahiro Abe :
骨病変/局所病変の管理 (特集 多発性骨髄腫診療の新時代を迎えて--診断と治療に吹き込む「新しい風」) -- (多発性骨髄腫の合併症の管理),
内科, Vol.108, No.2, 274-281, Aug. 2011.
(CiNii: 1390001288080663552)

Proceeding of International Conference:

1. Yamagami Hiroki, Yasui Saya, Hosoki Minae, Hori Taiki, Tomoyo Hara, Kiyoe Kurahashi, Sumiko Yoshida, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa, Itsuro Endo, Masahiro Abe and Ken-ichi Aihara :
Skin autofluorescence is associated with tubular injury represented by urinary excretion of liver-type fatty acid-binding protein in patients with diabetes,
American Diabetes Association 82nd Scientific Sessions, Jun. 2022.
2. Ken-ichi Aihara, Yamagami Hiroki, Yasui Saya, Hosoki Minae, Hori Taiki, Shingen Nakamura, Toshiki Otoda and Tomoyuki Yuasa :
Clinical Significance of Dehydroepiandrosterone Sulfate in Carotid Atherosclerosis and Nonalcoholic Fatty Liver Disease,
ESMED Congress 2021, Nov. 2021.
3. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Novel strategy of elotuzumab and zoledronic acid with Th1-like T cells against myeloma,
18th International Myeloma Workshop, Wien, Sep. 2021.
4. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Induction of elotuzumabs ADCC activity by Th1-like T cells towards osteoclasts as well as myeloma cells,
EHA2021 Virtual Congress, Jun. 2021.
5. Hirokazu Miki, Shingen Nakamura, Masafumi Nakamura, Makiko Mizuguchi, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Mamiko Takahasi, Tomoko Maruhashi, Takeshi Harada, Shiro Fujii, Kumiko Kagawa, Hirofumi Hamano, Masateru Kondou, Naoto Okada, Yoshimi Bando, Itsuro Endo and Masahiro Abe :
The importance of retaining physical functions to prevent skeletal-related events in multiple myeloma patients with bone disease.,
The 48th annual meeting of European Calcified Tissue Society (ECTS), Online, May 2021.
6. Yuka Sogawa, Makoto Fukui, Shingen Nakamura, Kimiko Sogabe, Ryohei Sumitani, Masami Yoshioka, Masahiro Abe and Daisuke Hinode :
Risk factors for chemotherapy-induced febrile neutropenia in hematological cancer patients,
106th Annual Meeting of American Academy of Periodontology, Honolulu, Nov. 2020.
7. Takeshi Harada, Asuka Oda, Hiroto Ohguchi, Yohann Grondin, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe :
Novel therapeutic rationale for targeting HDAC1 and PIM2 in multiple myeloma,
61th ASH Annual Meeting & Exposition, Orlando, Dec. 2019.
(DOI: 10.1182/blood-2019-127679)
8. Takeshi Harada, Asuka Oda, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shuji Ozaki, Teru Hideshima, C. Kenneth Anderson and Masahiro Abe :
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy,
17th International Myeloma Workshop, Sep. 2019.
9. Mohannad Ashtar, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Bat-Erdene Ariunzaya, Kimiko Sogabe, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Toshio Matsumoto, Masahiro Abe and Eiji Tanaka :
Peri-implantitis and the role of Febuxostat in osteoclast differentiation.,
AEEDC Dubai World Orthodontic Conference, Dubai, UAE, Feb. 2019.
10. Takeshi Harada, Asuka Oda, Yohann Grondin, Jumpei Teramachi, Ariunzaya Bat-Erdene, Masami Iwasa, Masahiro Oura, Shingen Nakamura, Kumiko Kagawa, Yasunobu Okamoto, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Shuji Ozaki, Teru Hideshima, Kenneth C. Anderson and Masahiro Abe :
The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis,
60th ASH Annual Meeting & Exposition, San Diego, Dec. 2018.
11. Shingen Nakamura, Hirokazu Miki, Ariunzaya Bat-Erdene, Yasunobu Okamoto, Kimiko Sogabe, Masahiro Oura, Mamiko Takahashi, Masami Iwasa, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma.,
Esmo asia 2018, Nov. 2018.
12. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Disruption of a progressive vicious cycle between myeloma tumor growth and bone destruction by TAK1 inhibition,
ASBMR 2018 Annual Meeting, Montreal, Sep. 2018.
13. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Ashtar Mohannad, Kotaro Tanimoto, Iwasa Masami, Bat-Erdene Ariunzaya, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Opposite effects of TRAIL on the Sp-1-c-FLIP survival pathway in myeloma cells and osteoclasts.,
ASBMR 2018 Annual Meeting, Montreal, Sep. 2018.
14. Takeshi Harada, Oda Asuka, Jumpei Teramachi, Bat-Erdene Ariunzaya, Iwasa Masami, Oura Masahiro, Shingen Nakamura, Kumiko Kagawa, Okamoto Yasunobu, Kimiko Sogabe, Shiroh Fujii, Hirokazu Miki, Hideshima Teru, Anderson C. Kenneth and Masahiro Abe :
Selective inhibition of class-I HDAC induces myeloma cell death through targeting IRF4-Pim-2 axis,
The 9th JSH International Symposium 2018 in Kyoto, Jul. 2018.
15. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Tatsuji Haneji, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction,
8th International Workshop on Advances in the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases and Cancer and Bone Society 2018 Meeting, Oxford, Jun. 2018.
16. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
TAK1 inhibition impairs myeloma cell-bone marrow interaction to reduce myeloma tumor growth and bone destruction,
American Society for Bone and Mineral Research (ASBMR) 2017 Annual Meeting, Denver, Sep. 2017.
17. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction,
International Society for Experimental Hematology 46th Annual Scientific Meeting, Frankfurt, Aug. 2017.
18. Hirofumi Tenshin, Jumpei Teramachi, A Oda, Ryota Amachi, Masahiro Hiasa, A Baterdene, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Osteoclasts utilize TRAIL for their NF-B activation, but TAK1 inhibition resumes TRAIL-induced apoptosis in osteoclasts.,
Australian and New Zealand Bone and Mineral Society 2017, Brisbane, Australia., Jun. 2017.
19. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Akihito Yamamoto, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of TAK1 inhibition on myeloma tumor progression and bone destruction,
Cancer and Bone Society Conference 2017, Indianapolis, May 2017.
20. Ryota Amachi, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Jumpei Teramachi, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Toshio Matsumoto, Eiji Tanaka and Masahiro Abe :
Osteoblast Creates a Non-permissive Niche for Myeloma Cells,
95th General Session & Exhibition of the IADR program book, San Francisco, Mar. 2017.
21. Shingen Nakamura and Momoyo Azuma :
Pseudo-outbreak of Mycobacterium chimaera in hematopoietic stem cell transplantation center due to sterile hand-washing machine,
ID week 2016, Vol.3, New Orleans, Oct. 2016.
(DOI: 10.1093/ofid/ofw172.1105)
22. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kiyoe Kurahashi, Takeshi Kondo, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma,
American Society for Bone and Mineral Research 2016 Annual Meeting, Atlanta, Sep. 2016.
23. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of TAK-1 inhibition on tumor growth and bone destruction in myeloma,
21st Congress European Hematology Association, Copenhagen, Jun. 2016.
24. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Derek Hanson, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Pim inhibition suppresses osteoclastogenesis and tumor growth in myeloma,
57th ASH Annual Meeting and Exposition, Orlando, Dec. 2015.
25. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, Asuka Oda, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Up-regulation of the pH sensor TRPV1 in myeloma cells and their adaption to an acidic microenvironment,
ASBMR 2015 Annual Meeting, Seattle, Oct. 2015.
26. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pivotal role of TAK-1 in tumor growth and bone destruction in myeloma: Therapeutic impact of TAK-1 inhibition,
American Society for Bone and Mineral Research 2015 Annual Meeting, Oct. 2015.
27. Hirokazu Miki, Shingen Nakamura, Hirofumi Tenshin, Ryota Amachi, Keiichiro Watanabe, Jumpei Teramachi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Effective impairment of myeloma progenitors by hyperthermia: augmentation with bortezomib and Pim inhibition in combination,
Clinical Lymphoma, Myeloma & Leukemia, Vol.15, No.S3, e217-e218, Sep. 2015.
(DOI: 10.1016/j.clml.2015.07.470)
28. Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Ryota Amachi, Keiichiro Watanabe, Jumpei Teramachi, Shiroh Fujii, Kumiko Kagawa and Masahiro Abe :
Alteration of Pim-2 expression by clinically available anti-myeloma agents: combinatory anti-myeloma effects with Pim inhibition,
Clinical Lymphoma, Myeloma & Leukemia, Vol.15, No.S3, e243, Sep. 2015.
(DOI: 10.1016/j.clml.2015.07.517)
29. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kumiko Kagawa, Hirokazu Miki, Shiroh Fujii, Keiichiro Watanabe, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Critical role of Pim-2 in NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis: Therapeutic impact of Pim inhibition on myeloma bone disease.,
2014 ASBMR Annual Meeting, Houston, Sep. 2014.
30. Keiichiro Watanabe, Masahiro Abe, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, H Mori, Itsuro Endo, Eiji Tanaka and Toshio Matsumoto :
Induction of bone formation in myeloma osteolytic lesions by cathepsinK inhibition,
Kyoto, Apr. 2013.
31. Ryota Amachi, Keiichiro Watanabe, Shiroh Fujii, T Harada, Hirokazu Miki, Shingen Nakamura, A Oda, Masahiro Hiasa, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
An acidic milieu suppersses histone acetylation in myeloma cells to down-regulate the TRAIL receptor DR4 expression.,
Kyoto, Apr. 2013.
32. Harada Takeshi, Ozaki Shuji, Oda Asuka, Iwasa Masami, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Shibata Hironobu, Akishige Ikegame, Daisuke Tsuji, Ito Kohji, Ri Masaki, Iida Shinsuke, Shiotsu Yukimasa, Kawai Shigeto, Yamada-Okabe Hisafumi and Toshio Matsumoto :
Combination therapy of a defucosylated anti-HM1.24 monoclonal antibody plus Ienalidomide induces marked antibody-dependent cellular cytotoxicity and inhibits the clonogenic potential of myeloma cancer stem-like cells. Atlanta, Dec. 2012.,
The 54th Annual Meeting of the American Society of Hamatology, Dec. 2012.
33. T Harada, Shuji Ozaki, A Oda, M Iwasa, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Hirofumi Shibata, Akishige Ikegame, Daisuke Tsuji, Kouji Itou, M Ri, S Iida, Y Shiotsu, S Kawai, H Yamada-Okabe and Toshio Matsumoto :
Combination Therapy of a Defucosylated Anti-HM1.24 Monoclonal Antibody Plus Lenalidomide Induces Marked Antibody-Dependent Cellular Cytotoxicity and Inhibits the Clonogenic Potential of Myeloma Cancer Stem-Like Cells.,
54th ASH Annual Meeting and Exposition, USA, Atlanta, Dec. 2012.
34. Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Harada Takeshi, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Prevention of tumor growth and bone destruction in myeloma by Pim kinase inhibition,
12th Int'l Meeting on Cancer Induced Bone Disease, Lyon, Nov. 2012.
35. Masahiro Hiasa, Ryota Amachi, Keiichiro Watanabe, Harada Takeshi, Fujii Shirou, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Pim-2 suppresses BMP-2 signaling as a common inhibitory mediator of osteoblastogenesis in myeloma,
ASBMR 2012 Anuual Meeting, Minneapolis, Oct. 2012.
36. Keiichiro Watanabe, Masahiro Abe, M Kawatani, Masahiro Hiasa, A Kawano, T Jinno, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, H Osada and Toshio Matsumoto :
Aggravation of myeloma growth and drug resistance by an acidic created in myeloma-osteoclast interaction.,
ASBMR 2011 Annual Meeting, San Diego, Sep. 2011.
37. Masahiro Hiasa, nakano ayako, Keiichiro Watanabe, C Qu, T Harada, Shiroh Fujii, Hirokazu Miki, Shingen Nakamura, Kumiko Kagawa, Kyoko Takeuchi, Eiji Tanaka, Kenzo Asaoka, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Prevention of tumor growth and bone destruction in myeloma by Pim kinase inhibition.,
ASBMR 2011 Annual Meeting, San Diego, Sep. 2011.
38. Masahiro Hiasa, nakano ayako, Keiichiro Watanabe, C Qu, T Harada, Shiroh Fujii, Hirokazu Miki, Shingen Nakamura, Kumiko Kagawa, Kyoko Takeuchi, Eiji Tanaka, Kenzo Asaoka, Shuji Ozaki, Toshio Matsumoto and Masahiro Abe :
Dual effects of Pim inhibition on myeloma: induction of bone formation and tumor suppression.,
IOF-ANZBMS 2011 Annual Meeting, Gold Coast, Sep. 2011.
39. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
An Acidic Mileu Created In Myeloma-Osteoclast Interaction Enhances Tumor Growth, but Triggers Anti-Myeloma Activity of Reveromycin A, a Novel Anti-Resorptive Agent,
52th American Society of Hematology, Orlando, Dec. 2010.
40. Cui Qu, Masahiro Abe, Miki Hirokazu, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Nakano Ayako, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
Lenalidomide In Combination with Zoledronic Acid Restores the Activation and Anti-Myeloma Effects of γδT Cells Attenuated by the Bone Marrow Microenvironment,
52th American Society of Hematology, Orlando, Dec. 2010.
41. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
A Novel Anti-resorptive Agent, Reveromycin A, Ameliorates Bone Destruction and Tumor Growth in Myeloma,
ASBMR 2010 Annual Meeting, Toronto, Oct. 2010.
42. Masahiro Hiasa, Masahiro Abe, nakano ayako, oda aska, amo hiroe, Keiichiro Watanabe, Shingen Nakamura, miki hirokazu, Kyoko Takeuchi, Kumiko Kagawa, Shuji Ozaki, Eiji Tanaka, Kenzo Asaoka and Toshio Matsumoto :
Bone Marrow Stromal Cells Suppress TACE-mediated M-CSFR and RANK Shedding to Facilitate Osteoclastogenesis and Suppress DC Differentiation from Monocytes.,
ASBMR 2010 Annual Meeting, Toronto, Oct. 2010.
43. Masahiro Abe, Masahiro Hiasa, Nakano A, Shingen Nakamura, Miki H, Qu C, Keiichiro Watanabe, Harada T, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
TIMP-3 up-regulation facilitates osteoclastogenesis and suppresses DC differentiation from monocytes in the bone marrow microenvironment in myeloma,
10th International Conference Cancer-induced Bone Disease, Sep. 2010.
44. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
The novel anti-resorptive agent reveromycin A ameliorates bone destruction and tumor growth in myeloma,
10th International Conference Cancer-induced Bone Disease, Sheffield (United Kingdom), Sep. 2010.

Proceeding of Domestic Conference:

1. Naoto Okada, Shingen Nakamura, Taro Shimizu, Hidenori ANDO, Fuka Aizawa, Takahiro Niimura, Kenta Yagi, Mitsuhiro Goda, Tatsuhiro Ishida and Keisuke Ishizawa :
免疫不全リスクを有する患者における 新型コロナワクチンによる抗体獲得能に 関連する因子の検討,
第32回日本医療薬学学会, Sep. 2022.
2. HORI Taiki, Shingen Nakamura, Minae Hosoki, Saya Yasui, Hiroki Yamagami, 滝下 誠 and Ken-ichi Aihara :
初発時にヘルペスウイルス属の再活性化と中枢浸潤を伴い急速に悪化した成人T細胞白血病リンパ腫の1例,
第126回日本内科学会四国地方会, Jun. 2022.
3. Shingen Nakamura, HORI Taiki, Minae Hosoki, Saya Yasui, Hiroki Yamagami, 赤澤 啓人, 滝下 誠 and Ken-ichi Aihara :
新型コロナワクチン接種後に発覚した自己免疫性出血病FXIII/13,
第126回日本内科学会四国地方会, Jun. 2022.
4. 本田 壮一, Shingen Nakamura, 高橋 啓輝, HORI Taiki and Masahiro Abe :
地域での造血腫瘍の診療を考える,
第126回日本内科学会四国地方会, Jun. 2022.
5. Shingen Nakamura, HORI Taiki, Minae Hosoki, Saya Yasui, Hiroki Yamagami, 滝下 誠, 答島 章公 and Ken-ichi Aihara :
血液疾患,自己免疫疾患における新型コロナワクチン接種後の抗体獲得能の検討,
第96回日本感染症学会総会, May 2022.
6. Shingen Nakamura, HORI Taiki, Masafumi Nakamura, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, 高橋 真美子, Shiroh Fujii, Hirokazu Miki, Takeshi Harada and Masahiro Abe :
Humoral response of the mRNA vaccine against SARS-CoV-2 in patients with plasma cell dyscrasia,
The 47th annual meeting of Japanese Society of Myeloma, May 2022.
7. Takeshi Harada, Ryohei Sumitani, Asuka Oda, Inoue Yusuke, Masahiro Oura, Kimiko Sogabe, Kimiko Sogabe, Tomoko Maruhashi, Takahashi Mamiko, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Therapeutic impact of targeting RNA editing enzyme ADAR1 on myeloma cells with 1q amplification,
第47回日本骨髄腫学会学術集会, May 2022.
8. 山上 紘規, 細木 美苗, HORI Taiki, 安井 沙耶, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
Skin Autofluorescenceの糖尿病性腎臓病における臨床的意義の解析,
第65回日本糖尿病学会年次学術集会, May 2022.
9. 細木 美苗, 山上 紘規, 安井 沙耶, HORI Taiki, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa and Ken-ichi Aihara :
当院10年間における死亡患者の年齢・死因および併存合併症における糖尿病と治療薬剤の影響,
第65回日本糖尿病学会年次学術集会, May 2022.
10. Hiroki Yamagami, Shingen Nakamura, Akihiro Tani, Minae Hosoki, Saya Yasui, Yoshihiro Miyata, 堀 太貴, 答島 章公, Ken-ichi Aihara and 滝下 誠 :
自己免疫疾患における新型コロナワクチンによる抗体獲得能の検討,
第119回日本内科学会総会, Apr. 2022.
11. HORI Taiki, Shingen Nakamura, Akihiro Tani, Minae Hosoki, Saya Yasui, Yoshihiro Miyata, Hiroki Yamagami, 答島 章公, Ken-ichi Aihara and 滝下 誠 :
血液疾患患者における新型コロナウイルスワクチン接種による抗体獲得能の検討,
第119回日本内科学会総会, Apr. 2022.
12. 辻 誠士郎, Sumiko Yoshida, 宮 恵子, 島久 登, 田代 学, 井上 朋子, 水口 潤, Shingen Nakamura, Itsuro Endo and Masahiro Abe :
65歳以上の透析患者における新型コロナワクチン抗体価の検討,
第33回日本老年医学会四国地方会, Jan. 2022.
13. HORI Taiki, Shingen Nakamura, Minae Hosoki, Saya Yasui, Hiroki Yamagami, 滝下 誠 and Ken-ichi Aihara :
血管中心性に浸潤し急速な経過で死に至った末梢性T細胞リンパ腫の1剖検例,
第125回日本内科学会四国地方会, Dec. 2021.
14. Hiroki Yamada, Rio Ohmori, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノムワイド関連解析によるビンクリスチン副作用発現関連遺伝子の同定と機械学習を用いた副作用発現予測モデルの構築,
第60回日本薬学会中国四国支部学術大会, Nov. 2021.
15. 細木 美苗, 山上 紘規, 安井 沙耶, HORI Taiki, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa and Ken-ichi Aihara :
当院死亡患者の年齢・死因および併存合併症における糖尿病の影響,
第59回日本糖尿病学会中国四国地方会, Oct. 2021.
16. Kimiko Sogabe, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, 小田 明日香, 井上 雄介, Ryohei Sumitani, 丸橋 朋子, Masahiro Oura, Shiroh Fujii, Kumiko Kagawa, Hirofumi Tenshin, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Resumption of myeloma cell sensitivity to proteasome inhibitors by PIM and Akt inhibition,
The 83rd Annual Meeting of the Japanese Society of Hematology, Sep. 2021.
17. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Expansion of γδT cells by CELMoDs and enhancement of their anti-myeloma effects by elotuzumab,
The 83rd Annual Meeting of Japanese Society of Hematology, Sep. 2021.
18. 細木 美苗, 山上 紘規, 安井 沙耶, HORI Taiki, Shingen Nakamura, Toshiki Otoda, Tomoyuki Yuasa and Ken-ichi Aihara :
糖尿病の有無からみた当院死亡患者の年齢・死因および併存合併症に関する検討,
第21回日本内分泌学会四国支部学術集会, Sep. 2021.
19. 庄野 隆志, Mariko Aoyama, 南城 和正, 山本 清成, Hidenori Maki, Tomohiro Inui, Shinichi Sakamoto, Tomoko Kobayashi, Shingen Nakamura, Hiromitsu Takizawa and Akira Tangoku :
アブスコパル効果を示した甲状腺原発形質細胞腫の1例,
第33回日本内分泌外科学会総会, Jun. 2021.
20. Shingen Nakamura :
Detection of hematological malignancies using N-NOSE (Nematode-NOSE),
Annals of Oncology, Vol.32, No.suppl4, S312, Jun. 2021.
(DOI: 10.1016/j.annonc.2021.05.622)
21. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Development of combinatory treatment of Th1-like γδT cells with elotuzumab against osteoclasts as well as myeloma cells,
第46回日本骨髄腫学会学術集会, May 2021.
22. Yohsuke Kaneko, Saya Yasui, Hiroki Yamagami, Taiki Hori, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
糖尿病患者における歩行速度規定臨床因子の解析,
第64回日本糖尿病学会年次学術集会, May 2021.
23. Ken-ichi Aihara, Taiki Hori, Hiroki Yamagami, Saya Yasui, Yohsuke Kaneko, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Masahiro Abe :
生体電気インピーダンス法による細胞外水分比および位相角と糖尿病患者における血中HbおよびHtレベルの連関解析,
第64回日本糖尿病学会年次学術集会, May 2021.
24. Hiroki Yamagami, Saya Yasui, Yohsuke Kaneko, Taiki Hori, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
糖尿病患者におけるDehydroepiandrosterone sulfate (DHEAS)の糖尿病性腎臓病進展および高血圧症罹患における意義,
第64回日本糖尿病学会年次学術集会, May 2021.
25. Saya Yasui, Hiroki Yamagami, Yohsuke Kaneko, Taiki Hori, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
糖尿病患者における非アルコール性脂肪肝疾患および骨格筋異常症におけるDehydroepiandrosterone sulfate (DHEAS)の意義,
第64回日本糖尿病学会年次学術集会, May 2021.
26. HORI Taiki, Shingen Nakamura, Minae Hosoki, Saya Yasui, Hiroki Yamagami, 滝下 誠 and Ken-ichi Aihara :
腫大リンパ節に著明なアミロイド沈着を認めたリンパ形質細胞性リンパ腫の1例,
第124回日本内科学会四国地方会, May 2021.
27. 金子 遥祐, Tomoyuki Yuasa, Takeshi Soeki, Toshiki Otoda, Tatsuya Taniguchi, Ken-ichi Aihara, 安井 沙耶, 堀 太貴, 山上 紘規 and Shingen Nakamura :
糖尿病患者における歩行速度規定臨床因子の解析,
Journal of the The Japan Diabetes Society, Vol.64, No.Suppl.1, III-133-4, May 2021.
28. 山上 紘規, 安井 沙耶, 金子 遥祐, 堀 太貴, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
糖尿病患者におけるDehydroepiandrosterone sulfate(DHEAS)の糖尿病性腎臓病進展および高血圧症罹患における意義,
Journal of the The Japan Diabetes Society, Vol.64, No.Suppl.1, P-35-6, May 2021.
29. Taiki Hori, Hiroki Yamagami, Saya Yasui, Yohsuke Kaneko, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki, Masahiro Abe and Ken-ichi Aihara :
生体電気インピーダンス法による細胞外水分比および位相角は糖尿病患者の血中HbおよびHtレベルを規定する,
第94回日本内分泌学会学術総会, Apr. 2021.
30. Hiroki Yamagami, Saya Yasui, Yohsuke Kaneko, Taiki Hori, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
Dehydroepiandrosterone sulfate (DHEAS)高値は糖尿病性腎臓病進展および高血圧症罹患のリスクとなる,
第94回日本内分泌学会学術総会, Apr. 2021.
31. Yohsuke Kaneko, Saya Yasui, Hiroki Yamagami, Taiki Hori, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
生活習慣病患者の歩行速度は骨格筋量よりも筋力が規定する,
第94回日本内分泌学会学術総会, Apr. 2021.
32. 金子 遥祐, 安井 沙耶, 山上 紘規, 堀 太貴, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
生活習慣病患者の歩行速度は骨格筋量よりも筋力が規定する,
Folia endocrinologica Japonica, Vol.97, No.1, 366, Apr. 2021.
33. 山上 紘規, 金子 遥祐, 安井 沙耶, 堀 太貴, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
Dehydroepiandrosterone sulfate(DHEAS)高値は糖尿病性腎臓病進展および高血圧症罹患のリスクとなる,
Folia endocrinologica Japonica, Vol.97, No.1, 340, Apr. 2021.
34. 安井 沙耶, 山上 紘規, 金子 遥祐, 堀 太貴, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
Dehydroepiandrosterone sulfate(DHEAS)は生活習慣病患者における非アルコール性脂肪肝疾患およびダイナペニアの発症抑制因子である,
Folia endocrinologica Japonica, Vol.97, No.1, 287, Apr. 2021.
35. 石田 卓也, Hirokazu Miki, 髙橋 真美子, 中村 昌史, 水口 槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 丸橋 朋子, 岡本 秀樹, Naoto Okada, 矢野 由美子, 高橋 真理, Tetsu Tomonari, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Keiko Aota, Hiroyoshi Watanabe and Masahiro Abe :
HIV感染血友病患者における臨床的特徴と今後の課題,
第262回徳島医学会学術集会, Mar. 2021.
36. Maruhashi Tomoko, Shiroh Fujii, Kumiko Kagawa, Nakamura Masafumi, Shiyori Kawata, Makiko Mizuguchi, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Takahashi Mamiko, Takeshi Harada, Shingen Nakamura, Hirokazu Miki and Masahiro Abe :
造血幹細胞移植(allo-SCT)が奏効したMLL遺伝子変異合併CML急性転化(CML-BP)の2例,
第43回日本造血細胞移植学会総会, Mar. 2021.
37. Momoyo Azuma, Shingen Nakamura and 吉田 志緒美 :
~抗酸菌症にチームで立ち向かう~最新の知見と新たな光~ 無菌手洗い装置によるMycobacterium chimaeraの偽アウトブレイク,
Japanese Journal of Chemotherapy, Vol.69, No.2, 177-178, Mar. 2021.
38. 安井 沙耶, 山上 紘規, 金子 遥祐, 堀 太貴, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
当院生活習慣病患者における骨格筋量に影響を与える因子の検討,
Folia endocrinologica Japonica, Vol.96, No.3, 822, Jan. 2021.
39. 山上 紘規, 安井 沙耶, 金子 遥祐, 堀 太貴, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
当院生活習慣病患者における握力と歩行速度に影響を与える因子の検討,
Folia endocrinologica Japonica, Vol.96, No.3, 822, Jan. 2021.
40. Minori Takei, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
機械学習による遺伝情報を用いた抗がん剤投与の味覚障害発現予測モデルの構築,
第59回中国四国支部学術大会, Dec. 2020.
41. Yuka Endoh, Hozumi Tashima, 岡田 直人, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノム情報を用いた機械学習によるシタラビン投与後の副作用発現予測モデルの構築,
第59回中国四国支部学術大会, Dec. 2020.
42. 清重 尚希, Ryohei Sumitani, 水口 槙子, 中村 昌史, Masahiro Oura, Kimiko Sogabe, 高橋 真美子, Takeshi Harada, Shiroh Fujii, 賀川 久美子, Masahiro Abe, Shingen Nakamura, Hirokazu Miki, 曽賀 愛未, 一宮 由貴 and Yuri Yamamoto :
急性転化をきたしたAYA世代慢性骨髄性白血病の1例,
Shikoku Acta Medica, Vol.76, No.5-6, 354-355, Dec. 2020.
43. 高原 実香, Nobuaki Yamamoto, Ryosuke Miyamoto, Koji Fujita, Yuishin Izumi, Ryohei Sumitani, Shingen Nakamura, Masahiro Abe, Hideki Shimazu and 西田 善彦 :
意識障害,高アンモニア血症を呈した78歳男性,
Shikoku Acta Medica, Vol.76, No.5-6, 346, Dec. 2020.
44. Hirokazu Miki, 悦子 李, 佃 恵里加, 小田 直輝, 瀧本 朋美, 中村 昌史, 水口 槙子, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 高橋 真美子, Takeshi Harada, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe and Shingen Nakamura :
Daratumumab投与による輸血関連検査への影響とその対策,
Shikoku Acta Medica, Vol.76, No.5-6, 341, Dec. 2020.
45. 宮田 好裕, 板垣 達三, 藤本 美幸, 答島 章公, 滝下 誠, 日比野 真吾 and Shingen Nakamura :
リツキシマブもしくはリツキシマブ併用化学療法を要した濾胞性リンパ腫の十二指腸病変の検討,
日本消化器病学会四国支部例会プログラム・抄録集, 60, Dec. 2020.
46. 市原 聖也, Ryohei Sumitani, 中村 昌史, 水口 槙子, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
ウイルス関連血球貪食症候群が疑われたアグレッシブNK細胞白血病の1例,
第123回日本内科学会四国地方会, Nov. 2020.
47. 金山 涼加, Kiyoe Kurahashi, 明比 祐子, Koichi Okamoto, Shingen Nakamura, Sumiko Yoshida, Itsuro Endo, Tetsuji Takayama and Masahiro Abe :
潰瘍性大腸炎とバセドウ病の治療中に汎血球減少を契機に自己免疫性胃炎が判明した一例,
第123回日本内科学会四国地方会, Nov. 2020.
48. Yohsuke Kaneko, Shingen Nakamura, Minae Hosoki, Saya Yasui, Hiroki Yamagami, HORI Taiki, 滝下 誠 and Ken-ichi Aihara :
アミカシンによるAPTT偽延長を来したSerratia marcescens菌血症の1例,
第123回日本内科学会四国地方会, Nov. 2020.
49. 金山 涼加 and Shingen Nakamura :
潰瘍性大腸炎とバセドウ病の治療中にLDH著明高値を伴った汎血球減少を契機に自己免疫性胃炎が判明した1例,
第123回日本内科学会四国地方会, Nov. 2020.
50. Kimiko Sogabe, Shingen Nakamura, Shiroh Fujii, Hirokazu Miki, 小田 明日香, Takeshi Harada, Ryohei Sumitani, Masahiro Oura, Kumiko Kagawa, Hirofumi Tenshin, Jumpei Teramachi, Masaki Ri, Shinsuke Iida and Masahiro Abe :
Immediate accumulation of anti-apoptotic PIM2 in myeloma cells by proteasome inhibitors,
第82回日本血液学会学術集会, Oct. 2020.
51. Masahiro Ohhra, Takeshi Harada, 寺町 順平, 小田 明日香, Yusuke Inoue, Kimiko Sogabe, Ryohei Sumitani, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Hasegawa Hiroo, Fujiwara Hiroshi and Masahiro Abe :
Critical roles of the TAK1-c-Myc loop as a novel therapeutic target for ATL,
第82回日本血液学会学術集会, Oct. 2020.
52. Kotaro Tanimoto, Masahiro Hiasa, Hirofumi Tenshin, Mohannad Ashtar, Sou Shimizu, Yoshiki Higa, Jumpei Teramachi, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
不動は骨吸収と骨髄腫進展を促進させる,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 149, Oct. 2020.
53. Hirofumi Tenshin, Mohannad Ashtar, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Sou Shimizu, Yoshiki Higa, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
抗腫瘍薬が誘導するROSは破骨細胞分化を促進する:Xanthine oxidase阻害剤febuxostatの治療効果.,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 148, Oct. 2020.
54. Takeshi Harada, Yusuke Inoue, Hirofumi Tenshin, Asuka Oda, Masahiro Oura, Kimiko Sogabe, Ryohei Sumitani, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Masahiro Hiasa, Jumpei Teramachi and Masahiro Abe :
Versatile anti-myeloma effects by elotuzumab: impact on γδT cells and osteoclasts,
The 82nd Annual Meeting of Japanese Soceity of Hematology, Oct. 2020.
55. Kiyoe Kurahashi, 村井 純平, 堀 太貴, Ryohei Sumitani, Takeshi Harada, Shingen Nakamura, Mai Kanai, Akiko Sakurai, 原 倫世, 桝田 志保, Sumiko Yoshida, Itsuro Endo, 松本 俊夫, Masahiro Abe and Seiji Fukumoto :
高1,25(OH)2D血症による高Ca血症を来したホジキンリンパ腫の一例,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 150, Oct. 2020.
56. Hirofumi Tenshin, アシテル モハナッド, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Sou Shimizu, 比嘉 佳基, Takeshi Harada, Masahiro Oura, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
抗腫瘍薬が誘導するROSは破骨細胞分化を促進する Xanthine oxidase阻害剤febuxostatの治療効果,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 148, Oct. 2020.
57. Masahiro Oura, Shingen Nakamura, 堀 太貴, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Tomoko Kobayashi, Takeshi Oya and Masahiro Abe :
結節性紅斑と悪性腫瘍関連血球貪食症候群を惹起した骨髄異形成症候群の1例,
The Japanese Journal of Clinical Hematology, Vol.61, No.10, 1542, Oct. 2020.
58. 中村 昌史, Hirokazu Miki, Masahiro Oura, 川田 知代, 堀 太貴, 村井 純平, Ryohei Sumitani, Kimiko Sogabe, 高橋 真美子, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, 菅崎 幹樹, 徳永 尚樹, Akishige Ikegame, 森下 英理子 and Masahiro Abe :
クロスミキシングテストの特徴的な所見が診断の契機となったプレカリクレイン欠乏症の1例,
The Japanese Journal of Clinical Hematology, Vol.61, No.10, 1537-1538, Oct. 2020.
59. Hiroki Yamagami, Saya Yasui, Yohsuke Kaneko, Taiki Hori, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
当院生活習慣病患者における握力と歩行速度に影響を与える因子の検討,
第20回日本内分泌学会四国支部学術集会, Sep. 2020.
60. Saya Yasui, Hiroki Yamagami, Yohsuke Kaneko, Taiki Hori, Shingen Nakamura, Tatsuya Taniguchi, Toshiki Otoda, Tomoyuki Yuasa, Takeshi Soeki and Ken-ichi Aihara :
当院生活習慣病患者における骨格筋量に影響を与える因子の検討,
第20回日本内分泌学会四国支部学術集会, Sep. 2020.
61. 堀 大貴, Shingen Nakamura, Takeshi Harada, Ryohei Sumitani, 村井 純平, 高松 信敏, Fumitake Tezuka and Masahiro Abe :
若年で発症しアトピー性皮膚炎に合併した化膿性脊椎炎の1例,
第123回日本内科学会四国地方会, Jul. 2020.
62. Naoto Okada, 神農 麻里奈, Shingen Nakamura, Hirokazu Miki, Hiroyoshi Watanabe, Mitsuhiro Goda, Masayuki Chuma, Kenshi Takechi, Yoshito Zamami, 桐野 靖, 中村 敏己, Kazuhiko Teraoka, Masahiro Abe and Keisuke Ishizawa :
血液凝固因子製剤の在庫適正化に向けた取り組みによる薬剤廃棄額の削減効果,
Journal of Japnese Society of Hospital Pharmacists, Vol.56, No.7, 803-808, Jul. 2020.
63. 山崎 佳那子, 祖川 麻衣子, Kazutoshi Murao, Yoshiaki Kubo, Masahiro Oura, Takeshi Harada, Shingen Nakamura and Kumiko Kagawa :
骨髄異形成症候群の患者に生じた晩発性皮膚ポルフィリン症の1例,
The Nishinihon Journal of Dermatology, Vol.82, No.3, 238-239, Jun. 2020.
64. 秦 真公人, 菅崎 幹樹, 井上 雄介, 多田 智紀, 吉田 裕子, Takayuki Nakao, Ryohei Sumitani, Shingen Nakamura, Masahiro Abe and Tetsuji Takayama :
特徴的な形態像を呈し鑑別に苦慮したIgDκ型多発性骨髄腫の一症例,
Journal of the Japanese Society for Laboratory Hematology, Vol.21, S244, Jun. 2020.
65. 村井 純平, 堀 太貴, 川田 知代, Ryohei Sumitani, 宇高 憲吾, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Masahiro Abe, Hirokazu Miki, 桝田 志保, Itsuro Endo and Seiji Fukumoto :
高ビタミンD血症による高Ca血症を来したホジキンリンパ腫の一例,
Shikoku Acta Medica, Vol.76, No.1-2, 124, Apr. 2020.
66. Yuka Endoh, Hozumi Tashima, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築,
日本薬学会 第140年会, Mar. 2020.
67. Minori Takei, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
遺伝情報を用いた機械学習による抗がん剤投与の味覚障害発現予測モデルの構築,
日本薬学会 第140年会, Mar. 2020.
68. 遠藤 優香, 田島 穂澄, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築,
日本薬学会年会要旨集, 26M-am07S, Mar. 2020.
69. Akiko Abe, Takeshi Iwasa, Yuri Yamamoto, Masami Morimoto, Shingen Nakamura and Akira Kuwahara :
徳島県におけるがん生殖医療の現状と課題,
Journal of Fertility Preservation, Vol.3, No.1, 106, Jan. 2020.
70. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Mohannad Ashtar, Bat-Erdene Ariunzaya, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1阻害は関節リウマチにおけるNLRP3インフラマソーム誘導性の炎症および骨破壊を抑制する,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 190, Oct. 2019.
71. Kotaro Tanimoto, Masahiro Hiasa, Akihiko Iwasa, Hirofumi Tenshin, Jumpei Teramachi, Mohannad Ashtar, Masami Iwasa, 小田 明日香, 曾我部 公子, Masahiro Oura, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる.,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, Oct. 2019.
72. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Mohannad Ashtar, Ariunzaya Bat-Erdene, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1阻害は関節リウマチにおけるNLRP3インフラマソーム誘導性の炎症および骨破壊を抑制する.,
第37回日本骨代謝学会学術集会, Oct. 2019.
73. 谷本 幸太朗, Masahiro Hiasa, Hirofumi Tenshin, Jumpei Teramachi, Mohannad Ashtar, Masami Iwasa, 小田 明日香, Kimiko Sogabe, Masahiro Oura, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
不動性骨吸収の亢進は骨髄内の骨髄腫進展を促進させる,
第37回日本骨代謝学会学術集会, Oct. 2019.
74. Sakaida Emiko, Kanda Yoshinobu, Kimura Shunichi, Shingen Nakamura and Tamura Kazuo :
D-index-guided early antifungal therapy for persistent FN in patients with hematological malignancies (CEDMIC trial),
Annals of Oncology, Vol.30, No.6, VI84, Oct. 2019.
(DOI: 10.1093/annonc/mdz339.008)
75. Yuka Sogawa, Masami Yoshioka, 南 明香, Makoto Fukui, Daisuke Hinode, Shingen Nakamura and Masahiro Abe :
自家末梢血幹細胞移植患者の口腔ケアによる口腔粘膜炎障害の低減効果,
第68回日本口腔衛生学会総会, May 2019.
76. 安宅 克博, Shingen Nakamura, Masahiro Oura, Kimiko Sogabe, Takeshi Harada, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Yasuhiko Nishioka and Masahiro Abe :
長期にわたる血小板減少が先行した芽球性形質細胞様樹状細胞腫瘍の1例,
第120回日本内科学会四国地方会, May 2019.
77. Yuto Tanigaki, Yuta Yamaguchi, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノムワイド関連解析を用いたテイコプラニン・バンコマイシン投与による皮疹発現および血中濃度関連遺伝子座の同定,
日本薬学会 第139年会, Mar. 2019.
78. Rio Ohmori, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
ゲノムワイド関連解析を用いたビンクリスチンによる末梢神経障害発現関連遺伝子の同定,
第57回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2018.
79. Yuta Yamaguchi, Yuto Tanigaki, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Youichi Sato :
CYP遺伝子多型とバンコマイシンの副作用発現及び血中濃度との関連解析,
第57回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Nov. 2018.
80. Jumpei Teramachi, Hirofumi Tenshin, Masahiro Hiasa, Oda Asuka, Bat-Erdene Ariunzaya, Takeshi Harada, Iwasa Masami, Shiroh Fujii, Kimiko Sogabe, Shingen Nakamura, Hirokazu Miki, Masahiro Oura, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Mechanisms of TAK1 over-activation in myeloma cells and TAK1-mediated myeloma growth and bone destruction,
第80回日本血液学会学術集会, Oct. 2018.
81. Masami Iwasa, Takeshi Harada, Bat-Erdene Ariunzaya, 小田 明日香, Kimiko Sogabe, Masahiro Oura, Jumpei Teramachi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
HDAC阻害による骨髄腫細胞のIFN-γ-STAT1- PD-L1経路の増強効果,
第80回日本血液学会学術集会, Oct. 2018.
82. Ashtar Mohannad, Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Oda Asuka, Iwasa Masami, Takeshi Harada, Ariunzaya Erdene Bat, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Roles of ROS in induction of bone disease and cancer treatment-induced bone loss in myeloma.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
83. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Mohannad Ashtar, Ariunzaya Bat-Erdene, Iwasa Masami, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Inverse regulation of c-FLIP-mediated survival in myeloma cells and osteoclasts by TRAIL.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
84. Kotaro Tanimoto, Masahiro Hiasa, Hirofumi Tenshin, Jumpei Teramachi, Oda Asuka, Mohannad Ashtar, Ariunzaya Bat-Erdene, Iwasa Masami, Kimiko Sogabe, Oura Masahiro, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Impact of denervation-induced paralysis and mechanical unloading on tumor expansion in myeloma.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
85. Masahiro Hiasa, Jumpei Teramachi, Hirofumi Tenshin, Kotaro Tanimoto, Ariunzaya Bat-Erdene, Mohannad Ashtar, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Kimiko Sogabe, Oura Masahiro, Shiroh Fujii, Kumiko Kagawa, Oda Asuka, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease.,
The 80th Annual Meeting of the Japanese Society of Hematology, Oct. 2018.
86. Masahiro Hiasa, Jumpei Teramachi, Hirofumi Tenshin, Kotaro Tanimoto, Mohannad Ashtar, Ariunzaya Bat-Erdene, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
カテプシンK阻害による多発性骨髄腫骨病変部の骨量 回復プロセスにおける骨細胞の役割.,
第36回日本骨代謝学会学術集会, Jul. 2018.
87. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, Kotaro Tanimoto, Mohannad Ashtar, Ariunzaya Bat-Erdene, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1阻害はTRAILによる破骨細胞活性化作用を遮断 させると同時にTRAILの抗骨髄腫作用を増強する,
第36回日本骨代謝学会学術集会, Jul. 2018.
88. Hirofumi Tenshin, Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Kotaro Tanimoto, Mohannad Ashtar, Ariunzaya Bat-Erdene, Masami Iwasa, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1による破骨細胞に対するTRAILの生存・細胞死シグナル制御機構.,
第4回日本骨免疫学会, Jun. 2018.
89. Kotaro Tanimoto, Masahiro Hiasa, Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Mohannad Ashtar, Ariunzaya Bat-Erdene, Masami Iwasa, Kimiko Sogabe, 大浦 雅弘, Takeshi Harada, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
神経切断による麻痺と免荷の骨髄腫の進展への影響.,
第4回日本骨免疫学会, Jun. 2018.
90. Masami Iwasa, Takeshi Harada, Bat-Erdene Ariunzaya, 小田 明日香, 前田 悠作, 高橋 真美子, Masahiro Oura, Jumpei Teramachi, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
Amplification of the IFN- γ -STAT1- PD-L1 pathway in myeloma cells by panobinostat,
The 43rd Annual Meeting of the Japanese Society of Myeloma, May 2018.
91. Takeshi Harada, Oda Asuka, Jumpei Teramachi, Bat-Erdene Ariunzaya, Iwasa Masami, Maeda Yusaku, Shingen Nakamura, Oura Masahiro, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hideshima Teru, Anderson C. Kenneth and Masahiro Abe :
HDAC1/3 inhibition disrupts the IRF4-Pim-2 pathway to induce effective myeloma cell death,
The 43rd Annual Meeting of the Japanese Society of Myeloma, May 2018.
92. Yuto Tanigaki, Youichi Sato, Yuta Yamaguchi, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
テイコプラニン投与による副作用発現および血中濃度とCYP遺伝子多型との関連解析,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
93. Hozumi Tashima, Youichi Sato, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
シタラビン投与による副作用発現と代謝経路関連遺伝子多型の関連解析,
第56回日本薬学会・日本薬剤師会・日本病院薬剤師会 中国四国支部学術大会, Oct. 2017.
94. Jumpei Teramachi, Masahiro Hiasa, Oda Asuka, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Masami Iwasa, Masahiro Oura, Yusaku Maeda, Shiroh Fujii, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Disruption of myeloma cell-bone marrow interaction by TAK-1 inhibition,
第80回日本血液学会学術集会, Oct. 2017.
95. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Masahiro Hiasa, Keiichiro Watanabe, Ariunzaya Baterdene, Masami Iwasa, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TRAILは破骨細胞を活性化させるが,TAK1阻害により骨髄腫細胞とともに破骨細胞にもTRAILのアポトーシス誘導活性が惹起できる,
The 35th Annual Meeting of the Japanese Society for Bone and Mineral Research (oral talk), Jul. 2017.
96. Rio Ohmori, Youichi Sato, Misaki Kiguchi, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
ビンクリスチンによる副作用発現とMDR1遺伝子多型との関連性,
第20回日本医薬品情報学会総会・学術大会, Jul. 2017.
97. Yuta Yamaguchi, Youichi Sato, Yuto Tanigaki, Naoto Okada, Shingen Nakamura, Kumiko Kagawa, Shiroh Fujii, Hirokazu Miki, Keisuke Ishizawa, Masahiro Abe and Aiko Yamauchi :
バンコマイシン投与による副作用発現及び血中濃度とCYP遺伝子多型との関連解析,
第20回日本医薬品情報学会総会・学術大会, Jul. 2017.
98. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Masahiro Hiasa, Baterdene Ariunzaya, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1阻害はTRAILの抗骨髄腫作用を増強するともに骨吸収促進活性を抑制活性に変換する.,
第42回日本骨髄腫学会, May 2017.
99. 天知 良太, Shingen Nakamura, Masahiro Hiasa, 小田 明日香, バットエルデネ アリウンザヤ, Jumpei Teramachi, Hirofumi Tenshin, Keiichiro Watanabe, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
骨形成誘導による骨髄腫細胞のエネルギー代謝の抑制,
第42回日本骨髄腫学会学術集会, May 2017.
100. 住谷 龍平 and Shingen Nakamura :
膵炎を契機に急性骨髄性白血病と診断した1例,
第115回内科学会四国地方会, Dec. 2016.
101. 岡本 恵暢, Shingen Nakamura, 上村 宗範, Ryohei Sumitani, 高橋 真美子, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe and Hirokazu Miki :
発熱と下肢対麻痺で発症した血管内大細胞型B細胞性リンパ腫の2例,
Shikoku Acta Medica, Vol.72, No.5-6, 236-237, Dec. 2016.
102. Kimiko Sogabe and Shingen Nakamura :
IVLBCLに対する自家PBSCT後にITP,小脳に限局した進行性多巣性白質脳症(PML)を発症した1剖検例,
第115回日本内科学会四国地方会, Nov. 2016.
103. Shingen Nakamura :
化学療法中や造血幹細胞移植後に発症した偽痛風の3例,
第115回日本内科学会四国地方会, Nov. 2016.
104. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
30. 天真寛文, 寺町順平, 小田明日香, 天知良太, , ,破骨細胞系細胞はアポトーシス誘引因子TRAILを生存促進・破骨細胞形成誘導因子として利用する:TAK1-Pim-2経路の役割,
第19回日本癌と骨病変研究会, Nov. 2016.
105. Naoko Matsui, Hiroki Yamazaki, Shingen Nakamura, Yuishin Izumi, 中道 一生, 西條 政幸 and Ryuji Kaji :
非HIV関連進行性多巣性白質脳症の3例,
第21回日本神経感染症学会, 228, Oct. 2016.
106. Jumpei Teramachi, Hiroshi Mori, Yasuo Ochi, Ryota Amachi, Asuka Oda, Masahiro Hiasa, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma.,
The 77th Annual Meeting of the Japanese Society of Hematology, Oct. 2016.
107. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TAK1 inhibition subverts TRAIL-mediated osteoclastogenesis.,
第77回日本血液学会学術集会,, Oct. 2016.
108. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, 小田 明日香, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, Shiroh Fujii, 遠藤 逸郎, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Mechanism of the TRPV1 up-regulatation in myeloma cells and adaptation to an acidic microenvironment.,
第77回日本血液学会学術集会,, Oct. 2016.
109. Keiichiro Watanabe, Jumpei Teramachi, Ryota Amachi, 小田 明日香, Hirofumi Tenshin, 岩浅 正美, Masahiro Hiasa, Shingen Nakamura, 遠藤 逸郎, 川谷 誠, 長田 裕之, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Amelotin gene expression is temporarily being upregulated at the initiation of apoptosis induced by TGFb1 in mouse gingival epithelial cells,
第77回日本血液学会学術集会,, Oct. 2016.
110. Shingen Nakamura :
Alteration of Pim-2 synthesis and degradation in myeloma cells by anti-myeloma agents.,
日本血液学会総会, Oct. 2016.
111. (名) ariunzaya and Shingen Nakamura :
Panobinostat and proteasome inhibitors cooperatvely degrade Sp1 to cause myeloma cell death,
日本血液学会総会, Oct. 2016.
112. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Shingen Nakamura, Kiyoe Kurahashi, Takeshi Kondo, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
TAK-1 inhibition disrupts Pim-2-associated and Pim-2-independent key signaling pathways to effectively suppress tumor growth and restore bone formation in myeloma,
第78回 日本血液学会学術集会, Oct. 2016.
113. Keiichiro Watanabe, Jumpei Teramachi, Ryota Amachi, 小田 明日香, Hirofumi Tenshin, Masahiro Hiasa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, 川谷 誠, 長田 裕之, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
リベロマイシンAによる酸性環境での骨髄腫細胞の治療抵抗性の克服,
日本骨代謝学会学術集会プログラム抄録集 (1349-0761)34回 Page183(2016.07), 183, Jul. 2016.
114. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
破骨細胞はTAK1の発現誘導を介しアポトーシスを抑制しTRAILにより成熟活性化される,
日本骨代謝学会学術集会プログラム抄録集 (1349-0761)34回 Page183(2016.07), 183, Jul. 2016.
115. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Hirofumi Tenshin, Ryota Amachi, 原田 武志, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
骨髄腫腫瘍進展と骨破壊病変形成におけるTAK1-Pim-2経路の役割,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, Jul. 2016.
116. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, 原田 武志, Hirofumi Tenshin, Shingen Nakamura, Ryota Amachi, Shiroh Fujii, Keiichiro Watanabe, Kumiko Kagawa, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pim-2は骨髄腫における破骨細胞形成促進の 必須媒介因子である,
第41回日本骨髄腫学会学術集会, May 2016.
117. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TRAILは破骨細胞に細胞死を誘導せず,破骨細胞分化・生存を促進する.,
第41回日本骨髄腫学会, May 2016.
118. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, A Oda, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, H Miki, Kumiko Kagawa, Shiroh Fujii, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Mechanism of the TRPV1 up-regulatation in myeloma cells and adaptation to an acidic microenvironment,
第77回日本血液学会学術集会, Oct. 2015.
119. Keiichiro Watanabe, Jumpei Teramachi, H Mori, Y Ochi, Ryota Amachi, A Oda, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, H Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
Potent induction of bone formation by anti-resorptive cathepsin K inhibitor in myeloma,
第77回日本血液学会学術集会, Oct. 2015.
120. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Potent suppression of osteoclastogenesis in myeloma by Pim inhibition,
第77回日本血液学会学術集会, Oct. 2015.
121. Jumpei Teramachi, Masahiro Hiasa, Asuka Oda, Hirofumi Tenshin, Ryota Amachi, Takeshi Harada, Keiichiro Watanabe, Shiroh Fujii, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Tumor reduction and bone restoration in myeloma by TAK-1 inhibition,
第77回日本血液学会学術集会, Oct. 2015.
122. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Hirofumi Tenshin, Ryota Amachi, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
Pim阻害による骨髄種骨病変の治療:破骨細胞形成の抑制,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, Jul. 2015.
123. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Hirofumi Tenshin, Ryota Amachi, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Tatsuji Haneji, Toshio Matsumoto and Masahiro Abe :
骨髄腫腫瘍進展と骨破壊病変形成における TAK-1の枢軸的役割,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, Jul. 2015.
124. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
TRAILは破骨細胞分化・生存を促進する:TAK-1による生と死の運命制御,
第1回日本骨免疫学会, 137, Jul. 2015.
125. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, 小田 明日香, Hirofumi Tenshin, Keiichiro Watanabe, Shingen Nakamura, Kumiko Kagawa, Hirokazu Miki, Shiroh Fujii, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
酸環境での骨髄腫細胞のDR4発現抑制:酸によるエピジェネティックな遺伝子発現制御,
第1回日本骨免疫学会, 108, Jul. 2015.
126. Ryota Amachi, Masahiro Hiasa, Jumpei Teramachi, 小田 明日香, Keiichiro Watanabe, Hirofumi Tenshin, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Takeshi Kondo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
酸性環境での骨髄腫細胞のTRPV1の発現亢進と酸環境への適応,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 165, Jul. 2015.
127. Hirofumi Tenshin, Jumpei Teramachi, 小田 明日香, Ryota Amachi, Masahiro Hiasa, Keiichiro Watanabe, Shingen Nakamura, Hirokazu Miki, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
アポトーシス誘導因子TRAILによる破骨細胞分化・生存の促進,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 164, Jul. 2015.
128. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, 原田 武志, Ryota Amachi, Hirofumi Tenshin, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Pim阻害による骨髄腫骨吸収亢進の抑制,
第40回日本骨髄腫学会学術集会, May 2015.
129. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, 原田 武志, Ryota Amachi, Hirofumi Tenshin, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, Kumiko Kagawa, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
TAK-1は骨髄腫腫瘍進展と骨破壊病変形成の枢軸的な媒介因子である,
第40回日本骨髄腫学会学術集会, May 2015.
130. Shingen Nakamura, Hirokazu Miki and Masahiro Abe :
Pim阻害薬と抗骨髄腫治療薬の併用効果の検討,
第40回 日本骨髄腫学会, May 2015.
131. Mayuri Nakano, Terumi Yoshijima, Masaki Hanibuchi, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Yasuhiko Nishioka :
Pneumocystis jiroveciに対しST合剤の脱感作療法を行った4症例の検討,
第89回日本感染症学会総会, Apr. 2015.
132. Shingen Nakamura, Momoyo Azuma, Hirokazu Miki, Kumiko Kagawa and Masahiro Abe :
当院で経験した重症熱性血小板減少症候群の3例,
第89回 日本感染症学会, Apr. 2015.
133. 丸橋 朋子, Shingen Nakamura, 曽我部 公子, 八木 ひかる, 高橋 真美子, 宇高 憲吾, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Masahiro Abe, Atsuro Saijo, Mayuri Nakano, Momoyo Azuma, Yasuhiko Nishioka, 近藤 憲保, 井内 新, 藤田 博己 and 馬原 文彦 :
当院で経験した重症熱性血小板減少症候群の3例,
第250回徳島医学会学術集会, Feb. 2015.
134. Jumpei Teramachi, Masahiro Hiasa, 原田 武志, Ryota Amachi, Kumiko Kagawa, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Therapeutic impact of Pim inhibition on myeloma bone disease: blockade of NF-B-mediated suppression of osteoblastogenesis and stimulation of osteoclastogenesis,
日本血液学会, Oct. 2014.
135. Ryota Amachi, Masahiro Hiasa, Keiichiro Watanabe, Jumpei Teramachi, 小田 明日香, Keiichiro Watanabe, Shingen Nakamura, Itsuro Endo, Eiji Tanaka, Toshio Matsumoto and Masahiro Abe :
酸が惹起する骨髄腫細胞の酸感受と生存シグナルの悪循環,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 225, Jul. 2014.
136. Jumpei Teramachi, Masahiro Hiasa, 小田 明日香, Ryota Amachi, Shingen Nakamura, Itsuro Endo, Toshio Matsumoto and Masahiro Abe :
Pim-2キナーゼはTNF-αによる骨芽細胞分化抑制および破骨細胞形成促進の必須媒介因子である:Pim阻害薬の骨髄腫骨病変改善効果,
第32回日本骨代謝学会学術集会, Jul. 2014.
137. Shingen Nakamura and Momoyo Azuma :
多発性骨髄腫におけるガラクトマンナン抗原検査の有用性,
Kansenshōgaku Zasshi, 2014.
138. Keiichiro Watanabe, Masahiro Abe, H Mori, K Udaka, M Iwasa, D Hanson, Ryota Amachi, Masahiro Hiasa, T Harada, Shiroh Fujii, Shingen Nakamura, H Miki, Kumiko Kagawa, Itsuro Endo, Eiji Tanaka and Toshio Matsumoto :
Bone restoration and tumor suppression in myeloma by cathepsin K inhibition with Bortezomib,
第75回日本血液学会学術集会, Oct. 2013.
139. 大黒 由加里, Takeshi Kondo, Shiroh Fujii, Shingen Nakamura, 倉橋 清衛, Akio Kuroda, Itsuro Endo, Ken-ichi Aihara, Munehide Matsuhisa and Toshio Matsumoto :
著名な汎血球減少と肝筋逸脱酵素高値を呈した神経性食欲不振症の一例,
第13回日本内分泌学会四国支部学術集会, Sep. 2013.
140. Hirokazu Miki, Shingen Nakamura, 竹内 恭子, 原田 武志, 岩佐 昌美, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe and Toshio Matsumoto :
赤芽球癆を合併した多中心性Castleman病の1例,
日本内科学会第107回四国地方会, Dec. 2012.
141. Motokazu Matsuura, Satoshi Yamada, Eriko Shibata, Kenji Watase, Fumi Kishi, Seiji Kishi, Akira Mima, Kojiro Nagai, Hideharu Abe, Shingen Nakamura, Masahiro Abe and Toshio Doi :
腎生検にてγ重鎖沈着症が疑われた糸球体沈着症の一例,
第42回日本腎臓学会西部学術大会, Oct. 2012.
142. Shiroh Fujii, Masahiro Abe, Ryota Amachi, Keiichiro Watanabe, Masahiro Hiasa, 竹内 恭子, 岩佐 昌美, 原田 武志, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa and Toshio Matsumoto :
Pim inhibition preferentially induces anti-myeloma activity in an acidic milien,
第74回日本血液学会学術集会, Oct. 2012.
143. Masahiro Hiasa, Masahiro Abe, Kumiko Kagawa, Hirokazu Miki, Shingen Nakamura, Harada Takeshi, Fujii Shirou, Keiichiro Watanabe, Ryota Amachi, Kenzo Asaoka and Toshio Matsumoto :
Pim-2 acts as a common downstream mediator to suppress bone formation in myeloma.,
第74回に本血液学会, Oct. 2012.
144. 原田 武志, Shuji Ozaki, 岩佐 昌美, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, Kumiko Kagawa, 柴田 泰伸, 重清 俊雄, 岡田 直人, 長尾 多美子, 鈴木 麗子, Shoji Sakiyama, Masahiro Abe and Toshio Matsumoto :
徳島県のエイズ拠点病院におけるHIV感染症及び後天性免疫不全症候群の現状,
第245回徳島県医学会学術総会, Jul. 2012.
145. Keiichiro Watanabe, Masahiro Abe, Ryota Amachi, Masahiro Hiasa, Shingen Nakamura, 遠藤 逸郎, 森 裕史, Eiji Tanaka and Toshio Matsumoto :
カテプシンK 阻害剤KK1-300-01 は骨髄腫骨病変部の骨破壊を抑制し骨形成を惹起する,
第30回日本骨代謝学会学術大会, 217, Jul. 2012.
146. Ryota Amachi, Masahiro Abe, Keiichiro Watanabe, Shingen Nakamura, Masahiro Hiasa, Eiji Tanaka and Toshio Matsumoto :
酸性環境は骨髄腫細胞にDR4 の発現抑制とcFLIP の活性化を惹起しTRAIL に対する抵抗性を獲得させる,
第30回日本骨代謝学会学術集会, 259, Jul. 2012.
147. 大黒 由加里, Shingen Nakamura, 岩佐 昌美, 原田 武志, Shiroh Fujii, Kumiko Kagawa, Masahiro Abe, Toshio Matsumoto and Hirokazu Miki :
腰痛と副腎不全症状で発症した両側副腎原発DLBCLの1例,
日本内科学会第106回四国地方会, Jun. 2012.
148. 原田 武志, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 中野 綾子, Kumiko Kagawa, 竹内 恭子, Masahiro Abe and Toshio Matsumoto :
徳島県における多発性骨髄腫の治療成績の検討,
第109回日本内科学会総会・講演会, Apr. 2012.
149. 原田 武志, Shuji Ozaki, 小田 明日香, 天羽 宏枝, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 中野 綾子, Kumiko Kagawa, 竹内 恭子, Masahiro Abe, 柴田 泰伸 and Toshio Matsumoto :
Lenalidomide 治療中の多発性骨髄腫患者におけるCRP上昇の検討,
第51回日本血液学会中国四国地方会, Mar. 2012.
150. Kumiko Kagawa, 原田 武志, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 竹内 恭子, Masahiro Abe and Toshio Matsumoto :
遺伝子組み替えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例,
第34回日本造血細胞移植学会, Feb. 2012.
151. Kumiko Kagawa, 原田 武志, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, 竹内 恭子, Masahiro Abe and Toshio Matsumoto :
遺伝子組み換えヒトトロンボモジュリン投与中に硬膜下血腫を来した同腫骨髄移植2症例,
第34回日本造血細胞移植学会, Feb. 2012.
152. Keiichiro Watanabe, Masahiro Abe, Q Cui, Masahiro Hiasa, M Kawatani, T Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki, A Nakano, K Kagawa, K Takeuchi, H Osada, Eiji Tanaka and Toshio Matsumoto :
Targeting an acidic microenvironment by reveromycin A to overcome drug resistance to myeloma cells and ameliorate bone disease.,
第36回日本骨髄腫研究会総会, Nov. 2011.
153. Masahiro Hiasa, Masahiro Abe, 中野 綾子, Kyoko Takeuchi, Kumiko Kagawa, Shingen Nakamura, Hirokazu Miki, Eiji Tanaka, Kenzo Asaoka, Ken-ichiro Yata and Toshio Matsumoto :
Pimキナーゼ阻害による腫瘍進展と骨破壊の抑制,
第73回日本血液学会, Oct. 2011.
154. Keisuke Fujioka, Atsuro Saijo, Yuko Toyoda, Souji Kakiuchi, Masaki Hanibuchi, Masahiko Azuma, Yasuhiko Nishioka, Kyoko Takeuchi, Shiroh Fujii, Shingen Nakamura, Kumiko Kagawa, Masahiro Abe and Tomoya Mizutani :
不明熱で発症し皮膚生検が診断に有効であった血管内リンパ腫の1例,
第243回徳島医学会学術集会, Jul. 2011.
155. Masahiro Hiasa, Masahiro Abe, 中野 綾子, Keiichiro Watanabe, Shingen Nakamura, Eiji Tanaka, Kenzo Asaoka and Toshio Matsumoto :
Pimキナーゼの阻害は骨芽細胞分化を促進し,骨髄腫骨病変の形成と腫瘍進展を抑制する,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 178, Jul. 2011.
156. Keiichiro Watanabe, Masahiro Abe, 川谷 誠, Masahiro Hiasa, Shingen Nakamura, Eiji Tanaka, 長田 裕之 and Toshio Matsumoto :
リベロマイシンAによる酸性環境がもたらす骨髄腫薬剤耐性の克服と骨病変形成の抑制,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 208, Jul. 2011.
157. Masahiro Hiasa, Masahiro Abe, 中野 綾子, Keiichiro Watanabe, Shingen Nakamura, Eiji Tanaka, Kenzo Asaoka and Toshio Matsumoto :
Pimキナーゼの阻害は骨芽細胞分化を促進し,骨髄腫骨病変の形成と腫瘍進展を抑制する,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 178, 2011.
158. Keiichiro Watanabe, Masahiro Abe, 川谷 誠, Masahiro Hiasa, Shingen Nakamura, Eiji Tanaka, 長田 裕之 and Toshio Matsumoto :
リベロマイシンAによる酸性環境がもたらす骨髄腫薬剤耐性の克服と骨病変形成の抑制,
The Annual Meeting of the Japanese Society for Bone and Mineral Research Program & Abstracts, 208, 2011.
159. Keiichiro Watanabe, Masahiro Abe, Cui Qu, Kawatani Makoto, Masahiro Hiasa, Nakano Ayako, Jinno Tadashi, Harada Takeshi, Shiroh Fujii, Shingen Nakamura, Miki Hirokazu, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki, Eiji Tanaka, Osada Hiroyuki and Toshio Matsumoto :
Reveromycin A prevents bone destruction and suppresses tumor growth in myeloma,
第72回日本血液学会, Dec. 2010.
160. Shingen Nakamura, Masahiro Abe, Cui Qu, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Miki Hirokazu, Nakano Ayako, Oda Asuka, Amo Hiroe, Jinno Tasashi, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
Bortezomib-induced osteoblast differentiation is hampered by excessive ER stress,
第72回日本血液学会, Sep. 2010.
161. Masahiro Hiasa, Masahiro Abe, 中野 綾子, 小田 明日香, 天羽 宏枝, Kyoko Takeuchi, Kumiko Kagawa, Shingen Nakamura, 三木 浩和, Ken-ichiro Yata, Keiichiro Watanabe, Shuji Ozaki, Kenzo Asaoka, Eiji Tanaka and Toshio Matsumoto :
Bone marrow stromal cells supress TACE activity in monocytes to induce osteoclastogenesis,
第72回日本血液学会, Sep. 2010.
162. Cui Qu, Masahiro Abe, Miki Hirokazu, Shingen Nakamura, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, Nakano Ayako, Jinnno Tadashi, Harada Takeshi, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
Bone marrow stromal cells attenuate gama delta T,
第72回日本血液学会, Sep. 2010.
163. Masahiro Hiasa, Masahiro Abe, 中野 綾子, 小田 明日香, 天羽 宏枝, Kyoko Takeuchi, Kumiko Kagawa, Shingen Nakamura, 三木 浩和, Ken-ichiro Yata, Keiichiro Watanabe, Shuji Ozaki, Kenzo Asaoka, Eiji Tanaka and Toshio Matsumoto :
骨髄間質細胞は,単球のTACE活性を抑制し樹状細胞分化を抑制し破骨細胞文化を誘導する,
第28回日本骨代謝学会, Jul. 2010.
164. Keiichiro Watanabe, Masahiro Abe, Kawatani Makoto, Masahiro Hiasa, Shingen Nakamura, Eiji Tanaka, 長田 裕之 and Toshio Matsumoto :
リベロマイシンAは骨髄腫骨破壊病変の形成と腫瘍進展を抑制する,
第28回日本骨代謝学会, Jul. 2010.
165. Shingen Nakamura, Masahiro Abe, Cui Qu, Keiichiro Watanabe, Akishige Ikegame, Masahiro Hiasa, 三木 浩和, 中野 綾子, 小田 明日香, 天羽 宏枝, 神野 雅, 原田 武志, Shiroh Fujii, Kumiko Kagawa, Kyoko Takeuchi, Shuji Ozaki and Toshio Matsumoto :
ボルテゾミブによる骨芽細胞分化の促進は過剰な小胞体ストレスによって抑制される,
第28回日本骨代謝学会, Jul. 2010.
166. Kumiko Kagawa, Ken-ichiro Yata, 田中 修, Shingen Nakamura, Hirokazu Miki, Kyoko Takeuchi, Masahiro Abe, Shuji Ozaki, Sumiko Yoshida and Itsuro Endo :
心筋への広範な直接浸潤を来したNK/T cell lymphoma 鼻型の一例,
第48回に本血液学会中国四国地方会, Mar. 2009.

Et cetera, Workshop:

1. 庄野 隆志, Mariko Aoyama, 南城 和正, 山本 清成, Hidenori Maki, Tomohiro Inui, Shinichi Sakamoto, Tomoko Kobayashi, Shingen Nakamura, Hiromitsu Takizawa and Akira Tangoku :
アブスコパル効果を示した甲状腺原発形質細胞腫の1例,
第49回中国四国甲状腺外科研究会(ハイブリッド開催), Feb. 2021.
2. 梶田 敬介, Shingen Nakamura, 曽我部 公子, 藤野 ひかる, 丸橋 朋子, Shiroh Fujii, Hirokazu Miki, Kumiko Kagawa, Hiroaki Toba and 阿部 正博 :
胸腺腫瘍に合併した赤芽球癆の二例-病態解明へのアプローチ-,
第252回徳島医学会学術集会, Feb. 2016.
3. Keiichiro Watanabe, Ryota Amachi, Masahiro Hiasa, Shingen Nakamura, Itsuro Endo, Hiroshi Mori, Eiji Tanaka and Toshio Matsumoto :
The cathepsinK inhibitor ONO-KK1-300-01 (ONO-KK1) prevents bone destruction and restores bone formation in myeloma bone lesions,
Bone Seminar, Aug. 2012.
4. Ryota Amachi, Masahiro Abe, Keiichiro Watanabe, Kumiko Kagawa, 藤井 志郎, 原田 武志, Hirokazu Miki, Shingen Nakamura, 小田 明日香, Masahiro Hiasa, Eiji Tanaka and Toshio Matsumoto :
酸環境は骨髄腫細胞のTRAILに対する抵抗性を増強する,
第3回骨バイオサイエンス研究会, Jul. 2012.
5. Masahiro Hiasa, Masahiro Abe, 中野 綾子, Keiichiro Watanabe, Kyoko Takeuchi, Kumiko Kagawa, Hirokazu Miki, Shingen Nakamura, Shiroh Fujii, 原田 武志, Shuji Ozaki, Eiji Tanaka, Kenzo Asaoka and Toshio Matsumoto :
Pimキナーゼの阻害による骨髄腫の進展抑制,
癌と骨病変研究会, Nov. 2011.
6. Masahiro Hiasa, Masahiro Abe, 中野 綾子, 小田 明日香, 天羽 宏枝, Kyoko Takeuchi, Kumiko Kagawa, Shingen Nakamura, 三木 浩和, Ken-ichiro Yata, Keiichiro Watanabe, Shuji Ozaki, Kenzo Asaoka, Eiji Tanaka and Toshio Matsumoto :
骨髄間質細胞は,単球のTACE活性を抑制し樹状細胞分化を抑制し破骨細胞文化を誘導する,
第17回徳島骨代謝研究会, Nov. 2010.
7. 倉橋 清衛, Shingen Nakamura, Sumiko Yoshida, Itsuro Endo, Ken-ichi Aihara, Yuichi Fujinaka, Toshio Matsumoto, Shusuke Yagi, Takashi Iwase, Masashi Akaike and Masataka Sata :
一酸化炭素中毒を契機に発見された急性心筋梗塞の一例,
第9回徳島総合診療研究会, Jul. 2009.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

  • がん化学療法後の全身性免疫炎症病態へのFusobacteriumの役割の解明 (Project/Area Number: 19K08839 )
  • Molecular mechanisms of activated osteoblast-induced myeloma death through mitochondrial impairment and metabolic perturbation (Project/Area Number: 16K18420 )
  • Exploration of mechanism of drug resisitance in cancer acidic condition and development of novel therapeutic drug (Project/Area Number: 26830108 )
  • 骨形成誘導と骨破壊性腫瘍の進展抑制を併せ持つ新たな分子標的薬の開発 (Project/Area Number: 25463087 )
  • Search by Researcher Number (10511321)